Hennion & Walsh Asset Management Inc. Sells 1,375 Shares of Thermo Fisher Scientific Inc. $TMO

Hennion & Walsh Asset Management Inc. lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 19.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 5,549 shares of the medical research company’s stock after selling 1,375 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $2,782,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC raised its stake in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at $170,000. Raymond James Financial Inc. raised its position in shares of Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after buying an additional 2,262 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.8%

Shares of NYSE TMO opened at $598.68 on Tuesday. The company has a market cap of $221.36 billion, a price-to-earnings ratio of 32.20, a PEG ratio of 2.42 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The stock has a 50-day moving average price of $519.74 and a two-hundred day moving average price of $509.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 26,553 shares of company stock worth $15,343,589. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher received FDA clearance for a multiple myeloma testing platform, strengthening its position in clinical diagnostics and potentially expanding adoption among hospitals, laboratories, and pharmaceutical companies. The development reinforces the company’s broader growth strategy in precision medicine. How Investors Are Reacting To Thermo Fisher Scientific New FDA-Cleared Multiple Myeloma Platform
• Positive Sentiment: Thermo Fisher expects its India customer base to grow 15% to 20% over the next five years as biopharmaceutical research and manufacturing expand in the country. The outlook points to a meaningful long-term international growth opportunity for the company’s instruments, services, and bioproduction businesses. Thermo Fisher Eyes India Customer Growth
• Positive Sentiment: Comparative coverage emphasizes Thermo Fisher’s stronger recent positioning in a potential recovery of pharmaceutical and biotechnology research spending. The company exceeded second-quarter expectations, raised guidance, and reported broad-based demand improvement, factors that can support investor confidence relative to peers such as Danaher. Thermo Fisher vs. Danaher
• Neutral Sentiment: Articles comparing Thermo Fisher with Abbott and Azenta frame the investment decision around diversification, valuation, and exposure to a life-sciences spending recovery. These are investor-perspective pieces rather than new company announcements, so their direct effect on TMO is limited. Abbott vs. Thermo Fisher Thermo Fisher and Azenta Comparison
• Negative Sentiment: CEO Marc Casper and Chief Accounting Officer Joseph Holmes sold shares. Both transactions were disclosed as part of planned trading activity, reducing the likelihood that the sales signal deteriorating business prospects, but insider selling can still create modest short-term sentiment pressure. Thermo Fisher Insider Trading Filing

Analyst Upgrades and Downgrades

TMO has been the topic of several research analyst reports. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Piper Sandler increased their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.